8-K current report · filed Sep 15, 2026

LB PHARMACEUTICALS INC (LBRX) 8-K Current Report: September 15, 2026

Item 5.02Item EX-99.1Item 7.01LBRX overview

Short answer

LB PHARMACEUTICALS INC (LBRX) filed an 8-K current report with the SEC on September 15, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item EX-99.1 (Exhibit EX-99.1), Item 7.01 (Regulation FD Disclosure). Susan G. Kozauer appointed Chief Medical Officer effective September 14, 2026, strengthening clinical-development leadership.

LB PHARMACEUTICALS INC 8-K event analysis

AI summary of each reported item and its exhibits

Item 5.02 · Departure/Election of Directors or Officers

  • Susan G. Kozauer appointed Chief Medical Officer effective September 14, 2026, strengthening clinical-development leadership
  • Prior experience at Centessa Pharmaceuticals and Intra-Cellular Therapies, relevant to advancing the Company’s pipeline
  • Annual base salary $515,000, with target bonus equal to 40% of salary
  • $150,000 sign-on bonus, earned over two years subject to continued employment
  • Inducement option for 200,000 shares, vesting over four years, creating potential shareholder dilution

Item 7.01 · Regulation FD Disclosure

  • Dr. Kozauer appointed Chief Medical Officer, strengthening clinical-development leadership
  • Appointment may influence trial execution, regulatory strategy and investor confidence
  • Press release details available in Exhibit 99.1

Item EX-99.1 · Exhibit EX-99.1

  • Susan G. Kozauer appointed Chief Medical Officer, strengthening clinical and regulatory leadership
  • Prior CAPLYTA development experience spans schizophrenia, mood disorders, pediatric indications, and multiple FDA approvals
  • Appointment arrives ahead of Phase 3 NOVA-2 schizophrenia topline results expected in the first half of 2027
  • Kozauer will lead LB-102 development across multiple neuropsychiatric indications
  • Key risks remain clinical, regulatory, funding, commercialization, and LB-102 execution dependence

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other LB PHARMACEUTICALS INC 8-K filings

Get the next LBRX 8-K as it lands

Follow LBRX for push alerts, or ask the research agent what this filing means.